Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration (NCT00460408), a registered phase not stated study. The primary outcome is Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection.

2. Clinical Question

3. Trial Design

This was a prospective epidemiologic cohort study of ocular safety in patients treated with Macugen for neovascular age-related macular degeneration in Europe. Its stated purpose was to gather additional safety information about intravitreal injections in real-world practice. The registry record also describes an interest in physician practice patterns and characteristics of patients treated with Macugen. The study is marked completed, with a start date of 2006-08 and primary completion of 2012-02.

The record identifies 501 enrolled participants and describes an observational study with no comparator. Allocation is not stated. The main treatment group is labelled Macugen; other listed groups are Macugen and Avastin, Macugen and Lucentis, and Macugen and Other AMD Drugs. These labels describe the registry’s safety groupings, not randomized assignments. They do not establish that the groups are comparable, mutually exclusive, or suitable for estimating a treatment effect.

The primary outcome concerns the incidence of pertinent ocular adverse events per injection from baseline up to 2 years. Secondary outcomes include incidence per injection reported by gender for males, by age groups, and the number of participants with serious hypersensitivity reactions. The age groups are up to 50 years, 51 to 64 years, 65 to 74 years, and 75 years or older. The registry record lists eight outcome measures in total, but a numerical estimate for the primary outcome is not reported in the registry record.

Because treatment was observed rather than assigned in a randomized comparison, differences between the listed groups could reflect patient characteristics, clinical decisions, exposure patterns, or other factors. The record does not report a protocol-level statistical plan, a sample-size justification, or details of interim analyses.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety Population: participants who received at least 1 Macugen (pegaptanib sodium) injection; in addition to endophthalmitis, results for POAE categories presented if number of specific POAEs was ≥1 in at least 1 reporting group.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection, measured over Baseline up to 2 years.

The primary endpoint is the incidence of pertinent ocular adverse events per injection, with follow-up described as baseline up to 2 years. The event categories are primarily endophthalmitis, along with increased intraocular pressure, vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. The registry defines the measure as the number of specific events divided by the total number of injections received. The safety population consists of participants who received at least one Macugen injection.

A per-injection measure describes events in relation to treatment exposure, rather than simply counting participants. It can therefore be useful when patients receive different numbers of injections. However, interpreting it requires attention to how events and injections were counted, whether events could be counted more than once, and how follow-up and exposure were handled. Those analysis details are not reported in the registry record.

The registry states that results for POAE categories were presented only if at least one specific event occurred in at least one reporting group, in addition to endophthalmitis. This is a reporting condition, not evidence that unreported categories had no events. The numerical primary endpoint result is not reported in the registry record, so its magnitude and precision cannot be assessed from the record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes an observational cohort in which patients receiving Macugen were followed for safety. In general, an observational cohort records exposures and outcomes as they occur in practice rather than assigning treatment at random. That design can document clinical experience, but it does not by itself separate the effect of a treatment from differences in patients, clinical practice, or other exposures. The registry record does not report the allocation method beyond identifying the study as observational and stating that allocation is not stated.

What does a per-injection incidence measure?

The primary endpoint is defined as the number of specific pertinent ocular adverse events divided by the total number of injections received. In general, an exposure-based measure relates events to the amount of treatment exposure. This can be informative when participants receive different numbers of injections, because a participant-level count alone does not represent how much exposure occurred. The registry record does not report the numerical event count, total injection count, or computed primary estimate, so the magnitude of this measure cannot be evaluated from the record.

Repeated injections also create a statistical issue. In general, injections received by the same person are not necessarily independent observations: a person’s health and history can affect both later exposure and later event risk. A method that treats every injection as unrelated to every other injection may understate uncertainty if within-person dependence is not handled. The registry record does not report the method used to account for repeated injections, if any. It also does not describe how an event was attributed to an injection or whether recurrent events were counted separately.

What can a confidence interval tell readers?

In general, a confidence interval expresses the uncertainty around an estimated quantity under the assumptions of the statistical method. A narrow interval indicates greater precision under those assumptions, while a wide interval indicates less precision. An interval is not a guarantee that the estimate is correct, and it does not resolve bias from selection, measurement, or confounding. The registry record does not report a confidence interval for the primary endpoint, so its precision cannot be assessed from the registered results.

Why does the absence of a comparator matter?

The record explicitly describes no comparator. Its separate safety groups include Macugen alone and Macugen used with other AMD drugs, but the registry does not identify these as randomized arms or a prespecified comparative design. In general, comparisons between nonrandomized groups may be affected by confounding: factors that influence both treatment patterns and outcomes can make groups differ for reasons other than the treatments being compared. The record does not report adjustment methods or a causal comparison. The group counts should therefore be read as descriptive safety information, not as estimates of relative treatment effects.

How should sparse event information be read?

In general, uncommon events can yield unstable estimates, especially when there are few observed events. The registry’s outcome definition says that POAE categories other than endophthalmitis were presented if at least one specific event occurred in at least one reporting group. That rule helps explain why some categories may not appear in reported results, but it does not show whether missing categories had zero events. The record does not provide the category-specific event counts or uncertainty estimates needed to examine sparse-event behavior.

Over-dispersion is a general concern when observed variability exceeds what a chosen statistical model assumes. For event counts, this can happen when risks vary across people or when events cluster within participants. A model that ignores extra variability can yield intervals that are too narrow. This is a general statistical consideration, not a description of a method used in this study; the registry record does not report a model or an over-dispersion assessment.

What do the subgroup outcomes address?

The secondary outcome descriptions specify per-injection reporting for males and for age groups up to 50 years, 51 to 64 years, 65 to 74 years, and 75 years or older. They also include the number of participants with serious hypersensitivity reactions. Subgroup descriptions identify questions the study intended to address, but a subgroup result requires both an estimate and enough information about the subgroup’s size and exposure. The numerical subgroup results and their analysis methods are not reported in the registry record.

More generally, subgroup estimates can be less precise than an overall estimate when they involve fewer participants or events. Apparent differences across subgroups can also arise by chance, especially when many outcomes or subgroup comparisons are examined. The registry record does not report a multiplicity plan or the analyses needed to assess subgroup differences. It is therefore not possible to determine from the registered information whether any subgroup pattern was statistically reliable.

The record identifies zero analyses and does not report the statistical plan, model specifications, confidence intervals, or missing-data procedures. Any further statistical method used by the investigators is not reported in the registry record. General discussion of exposure denominators, dependence, confounding, uncertainty, and sparse events describes considerations relevant to this design; it should not be read as a claim that a particular method was used.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists eight outcome measures, including the primary ocular adverse-event measure and secondary outcomes by gender and age group, as well as serious hypersensitivity reactions. When a study examines multiple outcomes or subgroups, the chance of observing an apparently notable result by chance can increase. In general, multiplicity procedures can address that issue, but they may affect the interpretation of estimates and tests. Whether any multiplicity adjustment was planned or used is not reported in the registry record.

The registry record lists zero analyses and does not report a statistical analysis plan, specific hypothesis tests, confidence intervals, or a hierarchy for interpreting outcomes. It is therefore not possible to determine which analyses were prespecified, how the secondary measures were handled, or whether any subgroup findings were intended as confirmatory or descriptive.

The safety population is defined as participants who received at least one Macugen injection. This is an exposure-based population definition, rather than an intention-to-treat definition for randomized assignments; the study is observational and has no comparator. The record does not describe exclusions after enrollment, the number of participants contributing to each outcome, or how follow-up differed across participants.

Missing-data methods are not reported in the registry record. It does not describe how incomplete follow-up, missing injection records, or unavailable outcome information were handled. In general, missingness can affect estimates when the likelihood of missing information is related to health status, treatment exposure, or the outcome. Without a reported method and information about missing observations, the direction or extent of any effect cannot be assessed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: urosepsis (1.3%), colon cancer (1.3%), lymphoma (1.3%), tachycardia (0.5%), pulmonary embolism (0.5%).

The serious adverse-event figures are listed by registry group. For Macugen, 403 participants were at risk and 21 were affected; for Macugen and Avastin, 16 were at risk and 0 were affected; for Macugen and Lucentis, 75 were at risk and 2 were affected; and for Macugen and Other AMD Drugs, 7 were at risk and 0 were affected. These are counts, not comparative estimates adjusted for group differences or exposure time. The registry record does not explain whether the group categories overlap or how follow-up time was handled.

The record also lists urosepsis at 1.3%, colon cancer at 1.3%, lymphoma at 1.3%, tachycardia at 0.5%, pulmonary embolism at 0.5%, and atrial fibrillation at 0.2% among the top serious terms. The denominator and calculation basis for these percentages are not reported in the registry record. Death counts are not reported in the registry record.

These figures describe recorded safety information. They do not establish that Macugen caused the events, and the absence of an affected participant in a listed group does not establish that an event is impossible or that no unrecorded event occurred.

12. What the Result Does, and Does Not, Mean

The registry record establishes the study’s purpose and design: a prospective observational cohort intended to add real-world safety information about Macugen injections for neovascular age-related macular degeneration in Europe. It defines the primary measure as pertinent ocular adverse events per injection and identifies the safety population as participants who received at least one injection. It also reports selected serious adverse-event counts across the listed treatment groups.

The record does not report a numerical primary endpoint estimate. Readers therefore cannot use the registry record to determine the observed incidence per injection or its precision. The secondary outcome descriptions also do not supply numerical estimates. The listed serious-event counts and terms provide limited descriptive information, but the record does not report the denominator basis for the term percentages or the methods used to analyze the safety data.

In general, a prospective cohort can document events occurring during care and can describe patterns in the population under observation. Without random assignment and a suitable comparator, however, it cannot by itself establish that an exposure caused an outcome. Patients receiving different drug combinations may differ in ways relevant to safety, and the registry record does not report adjustments intended to address those differences.

The result therefore supports a narrow interpretation: the registry record documents an observational safety study and records some adverse-event counts, while leaving the primary per-injection result and important analysis details unreported. It does not establish a comparative safety effect, explain the cause of individual events, or demonstrate that an event did not occur simply because a category is not listed. The limitations concern what can be concluded from the registry record; they do not imply that no further study information exists outside it.

13. Why This Trial Matters Statistically

Safety studies in routine practice address questions that may not be fully captured by a treatment efficacy comparison. This cohort was designed to collect information about ocular adverse events during Macugen use and to describe treatment practice and patient characteristics in Europe. The per-injection definition is statistically important because it relates the specified events to exposure, rather than reporting only a count of participants.

The design also illustrates why a clear estimand and an explicit analysis description matter. Interpreting a per-injection outcome depends on how events and injections are counted, how repeated observations within a participant are handled, and how follow-up contributes to the denominator. Those details are not reported in the registry record. Without them, readers cannot evaluate the numerical primary outcome or its precision; in this record, the primary estimate itself is also not reported.

The study’s observational nature is central to interpretation. The listed groups include Macugen alone and combinations with other AMD drugs, but they are not randomized comparator arms. Their safety counts may help describe recorded events, yet they do not establish comparative treatment effects. A registry report can therefore be informative about the intended safety questions while still leaving causal interpretation unsupported.

Finally, the distinction between an outcome definition and an outcome result is essential. The record specifies the events of interest, follow-up period, and safety population, but the numerical per-injection finding is not reported. Recognizing that distinction prevents a study objective from being mistaken for evidence of a particular result.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation for interpreting the primary question is that a numerical estimate of pertinent ocular adverse events per injection is not reported in the registry record. No uncertainty interval is reported for that endpoint. The outcome definition alone cannot show the frequency or precision of the events.

The study has no comparator, and allocation is not stated. The listed groups combine Macugen with different AMD drug labels, but the record does not establish that these are comparable groups or that they are mutually exclusive. Their counts should not be treated as direct treatment comparisons. The record does not report methods to adjust for differences between patients or treatment patterns.

The endpoint is based on injections, but the registry record does not describe the total number of injections, within-participant dependence, event recurrence rules, or the handling of differing follow-up. These details matter to the interpretation of an exposure-based rate. The record also does not describe missing-data handling or completeness of follow-up.

Although secondary outcomes are listed by gender and age group, their numerical results and analysis methods are not reported in the registry record. The record does not report whether subgroup analyses were prespecified or how multiple outcomes were handled. The percentages for top serious-event terms are listed without a reported denominator basis, and death counts are not reported in the registry record.

These limitations restrict interpretation of the registered information. They do not establish that the study failed to collect further data, only that the relevant estimates and methods are not reported in the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration — NCT00460408.
• Registry record last updated 2012-12-11; status last verified 2012-11.
• Results first posted 2012-12-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00460408 is a completed prospective epidemiologic cohort study of ocular safety in patients receiving Macugen for neovascular age-related macular degeneration in Europe. The registry record reports enrollment of 501 participants, a start date of 2006-08, and primary completion of 2012-02. The study is observational and has no comparator.

The primary outcome is pertinent ocular adverse events per injection from baseline up to 2 years, defined using specific event counts divided by total injections. Secondary outcomes include reporting by gender and age group and serious hypersensitivity reactions. A numerical primary outcome estimate and detailed statistical methods are not reported in the registry record. Selected serious adverse-event counts are reported for Macugen and for groups listed with other AMD drugs, but they do not establish comparative or causal effects.